Product Details
Synonyms
Oncostatin-M-specific receptor subunit beta, Interleukin-31 receptor subunit beta, IL-31 receptor subunit beta, IL-31R subunit beta, IL-31R-beta, IL-31RB, OSMR, OSMRB
Source
Canis lupus OSMR beta Protein, His Tag (OSR-C52H8) is expressed from human 293 cells (HEK293). It contains AA Glu 28 - Leu 737 (Accession # XP_038519803.1).
Predicted N-terminus: Glu 28
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 82.8 kDa. The protein migrates as 95-116 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Canis lupus OSMR beta Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS

The purity of Canis lupus OSMR beta Protein, His Tag (Cat. No. OSR-C52H8) is more than 90% and the molecular weight of this protein is around 105-125 kDa verified by SEC-MALS.
Report
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Oncostatin-M-specific receptor subunit beta
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
1 Details
- Highest Development Stage:
Phase 2 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















